Plain English Summary
Background and study aims
Drug CCX507-B is being studied as a possible treatment for patients with inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) or Crohns disease (CD). Patients with these diseases suffer considerable lifestyle disruption and disability due to their condition. As the disease progresses, it often leads to patients needing repeated surgeries to remove affected areas of the stomach and intestine. Therefore, a critical need for safe and effective non-surgical treatment of UC still remains.
Who can participate?
This study will include 30 healthy men and women aged 18-65.
What does the study involve?
The subjects will be randomly allocated to take CCX507-B or a placebo (sugar pill), administered orally. First, they will consume this pill once and later, they will consume this pill for a week. Participants will be followed up for 3 weeks.
What are the possible benefits and risks of participating?
Since this study mainly looks at the safety and tolerability of CCX507-B, there is likely no benefit for study subjects, other than the knowledge that they are potentially helping us understand how to use the medication in future studies. Safety risk is considered to be low, because CCX507-B has been tested safely in nonclinical studies.
Where is the study run from?
Pharmaceutical Research Associates Group B.V., Netherlands.
When is the study starting and how long is it expected to run for?
This study started in April 2014 and runs until June 20154.
Who is funding the study?
ChemoCentryx, Inc. (USA).
Who is the main contact?
Ms Antonia Potarca
apotarca@chemocentryx.com
Study website
Contact information
Type
Scientific
Contact name
Ms Antonia Potarca
ORCID ID
Contact details
850 Maude Avenue
Mountain View
94043
United States of America
650-210-2900
apotarca@chemocentryx.com
Additional identifiers
EudraCT/CTIS number
IRAS number
ClinicalTrials.gov number
Protocol/serial number
CL002_507
Study information
Scientific title
A double-blind, placebo-controlled, single and multiple ascending dose phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of CCX507-B in healthy male and female subjects
Acronym
Study hypothesis
CCX507-B will be safe and well tolerated at all dose levels tested.
Ethics approval(s)
The Independent Ethics Committee of the Foundation Evaluation of Ethics in Biomedical Research, Assen, the Netherlands,10/03/2014
Study design
Double-blind placebo-controlled study with two study periods. Period 1 will be a single dose period and Period 2 will be a multiple dose period.
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Study setting(s)
Hospital
Study type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Inflammatory Bowel Diseases (IBD) such as ulcerative colitis (UC) or Crohns disease (CD)
Intervention
CCX507-B (30, 60 and 90 mg CCX507-B single dose and multiple doses for 7 days) or placebo. Period 1 involves subjects being randomized to CCX507-B or placebo and being dosed a single time. Period 2 involved subjects being randomized to CCX507-B or placebo and being dosed over a period of 7 days. After the conclusion of Period 2, subjects are followed for 3 weeks.
Intervention type
Drug
Pharmaceutical study type(s)
Phase
Phase I
Drug/device/biological/vaccine name(s)
CCX507-B
Primary outcome measure
Safety and tolerability of CCX507-B. Safety is measured by adverse event, serum chemistry, urinalysis, and hematology assessments at Baseline, Days 2 and 4 after the single dose and Baseline, Days 2, 4, 8 and 15 of the multi-dose period.
Secondary outcome measures
Pharmacokinetic and pharmacodynamic profiles of CCX507-B. Pharmacokinetic profile is assessed on all study days, i.e., Days 1 through 4 of the single dose period and Days 1 through 15 of the multi-dose period. Pharmacodynamic markers are assessed at Baseline and on Days 1 and 2 of the single-dose period, and at Baseline and on Days 1, 2, 4, 5, 7, and 8 of the multi-dose period.
Overall study start date
30/04/2014
Overall study end date
30/06/2014
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Male or female subjects, aged 18-65 inclusive
2. Willing and able to give written Informed Consent and to comply with the requirements of the study protocol
3. Negative result of the human immunodeficiency virus (HIV) screen, the hepatitis B screen, and the hepatitis C screen
4. Female subjects of childbearing potential, and male subjects with partners of childbearing potential, may participate if adequate contraception is used
Participant type(s)
Patient
Age group
Adult
Lower age limit
18 Years
Upper age limit
65 Years
Sex
Both
Target number of participants
30
Participant exclusion criteria
1. Women who are pregnant or breastfeeding
2. History of use of tobacco and/or nicotine-containing products within the 3 months prior to study entry
3. History of drug abuse within 1 year prior to study entry
4. History of alcohol abuse within 5 years prior to study entry
5. History of any form of cancer
6. Consumed alcoholic beverages, or any food or drink containing grapefruit or Seville oranges within 48 hours prior to Day -1
7. History or presence of any medical condition or disease which, in the opinion of the Investigator, may place the subject at unacceptable risk for study participation
8. Donated or lost more than 50 mL of blood or blood products within 56 days prior to screening, or donated plasma within 7 days of randomization
8. Subject's hemoglobin less than the lower limit of normal at screening
9. Participated in any clinical study of an investigational product within 60 days prior to randomization
10. Subject has any evidence of hepatic disease; aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, or bilirubin > 1.5 x the upper limit of normal
11. Subject has any evidence of renal impairment; serum creatinine > 1.5 x upper limit of normal
12. Subject's urine tested positive at Screening and/or on Study Day -1 for any of the following: opioids, amphetamines, cannabinoids, benzodiazepines, barbiturates, cocaine, cotinine, or alcohol
Recruitment start date
30/04/2014
Recruitment end date
30/06/2014
Locations
Countries of recruitment
Netherlands, United States of America
Study participating centre
850 Maude Avenue
Mountain View
94043
United States of America
Sponsor information
Organisation
ChemoCentryx, Inc. (USA)
Sponsor details
850 Maude Avenue
Mountain View
94043
United States of America
Sponsor type
Industry
Website
ROR
Funders
Funder type
Industry
Funder name
ChemoCentryx, Inc. (USA)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Individual participant data (IPD) sharing plan
IPD sharing plan summary
Not provided at time of registration
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|